Edmond DE Rothschild Holding S.A. Sells 33,386 Shares of QIAGEN N.V. $QGEN

Key Points

• Edmond DE Rothschild Holding S.A. reduced its stake in Qiagen N.V. by 6.4% during the first quarter, now owning 490,970 shares valued at approximately $19.62 million.
• Other institutional investors, such as Wellington Management and Deutsche Bank, significantly increased their holdings in Qiagen, indicating strong market interest with 70% of the stock currently owned by institutional investors.
• Analysts have mixed ratings for Qiagen, with target prices ranging from $48.00 to $55.00, reflecting a generally cautious outlook despite a recent earnings report that met consensus estimates.

Edmond DE Rothschild Holding S.A. reduced its stake in QIAGEN N.V. (NYSE:QGEN - Free Report) by 6.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 490,970 shares of the company's stock after selling 33,386 shares during the period. Edmond DE Rothschild Holding S.A. owned approximately 0.22% of QIAGEN worth $19,618,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. AQR Capital Management LLC boosted its stake in QIAGEN by 69.4% in the 1st quarter. AQR Capital Management LLC now owns 178,425 shares of the company's stock valued at $7,164,000 after buying an additional 73,122 shares in the last quarter. Graham Capital Management L.P. lifted its holdings in shares of QIAGEN by 92.7% during the first quarter. Graham Capital Management L.P. now owns 68,114 shares of the company's stock valued at $2,735,000 after acquiring an additional 32,774 shares during the period. Vident Advisory LLC acquired a new stake in shares of QIAGEN in the 1st quarter valued at $604,000. State of Wyoming grew its holdings in shares of QIAGEN by 358.2% in the 1st quarter. State of Wyoming now owns 12,775 shares of the company's stock worth $513,000 after purchasing an additional 9,987 shares during the last quarter. Finally, Oak Harvest Investment Services acquired a new stake in shares of QIAGEN during the 1st quarter worth about $3,188,000. 70.00% of the stock is owned by institutional investors and hedge funds.

QIAGEN Trading Up 1.1%

Shares of QGEN stock traded up $0.50 on Friday, reaching $47.54. 939,634 shares of the stock were exchanged, compared to its average volume of 1,350,406. The stock has a market cap of $10.57 billion, a PE ratio of 28.08, a P/E/G ratio of 2.51 and a beta of 0.64. QIAGEN N.V. has a one year low of $37.63 and a one year high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The stock has a 50 day moving average price of $48.65 and a 200 day moving average price of $44.38.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. The business had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Analysts Set New Price Targets

QGEN has been the subject of several analyst reports. Wall Street Zen downgraded shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Bank of America lifted their target price on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Cowen reissued a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Barclays started coverage on QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target on the stock. Finally, UBS Group lifted their price objective on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Three analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $49.69.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.